Our comprehensive test menu has been created to aid in diagnosis and treatment selection across the full spectrum of hematologic disorders. We have developed and validated practice-based, data-driven algorithms that improve patient care, increase efficiency, and reduce costs. Our hematology experts continuously drive innovation in laboratory testing, developing new approaches and using new technology to address patient needs they see every day in clinical practice.
“We’re able to collaborate and hopefully contribute to patient care in a significant way, helping to establish standards for patients all over the world that may end up being diagnosed with this disease.”
David Viswanatha, M.D., co-director of the Molecular Hematopathology Laboratory
Our difference
The latest
Mayo Clinic researchers identify a new subtype of MGTS, linked to recurrent blood clots, with significant diagnostic challenges and treatment implications.
Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Dong Chen, M.D., Ph.D., chair of the Division of Hematopathology in the Department of Laboratory Medicine and Pathology at Mayo Clinic. They discuss rare and inherited platelet disorders and esoteric laboratory testing of hematologic disorders.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., interviews Ewa Wysokinska, M.D., an assistant professor of medicine and consultant in the division of hematology and oncology at Mayo Clinic in Florida, to talk about clinical updates in thrombotic thrombocytopenic purpura.
Presented by Mayo Clinic Laboratories, the Classical Hematology Conference, happening Oct. 15–17, is an essential event for professionals in hematology, including medical practitioners, researchers, and laboratory specialists.
Join us for the Classical Hematology Conference: Nonmalignant Hematology and Bleeding and Thrombotic Disorders, presented by Mayo Clinic Laboratories. This hybrid conference held Oct. 15–17, 2024, in Scottsdale, Arizona, will provide reviews and updates about the laboratory and clinical aspects of nonmalignant hematology and bleeding and thrombotic disorders.
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
On the brink of losing her battle with acute myeloid leukemia, Shannon Camlek arrived at Mayo Clinic as a last hope. Her chances didn’t look good, but with the help of specialized genetic testing, particularly FISH (fluorescence in situ hybridization) studies, doctors were able to detect the specific gene mutations responsible for her symptoms and disease. The test results also helped Shannon’s care team target her treatment accordingly, and finally put an end to what Shannon likens as starring in her own personal horror movie while in search of hope and healing.
One summer morning, James Kypuros awoke to find his toes stiffened like claws. Then he started having falls, which culminated in losing his ability to walk or even sit up without help. Diagnosed with stiff-person syndrome, James wouldn’t find hope or relief until he was treated for glycine receptor antibody syndrome following specialized testing by Mayo Clinic.
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately determine subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy.
Mayo Clinic Laboratories is excited to participate in the 65th ASH Annual Meeting & Exposition, which will take place in San Diego on Dec. 9–12, 2023.
In this month's "Hot Topic," Patricia Greipp, D.O., discusses fluorescence in situ hybridization, or FISH testing, particularly related to pediatric patients with hematologic malignancies.